Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Elias J. Jabbour
Elite in Acute Myelomonocytic Leukemia
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology
Elite in Acute Myelomonocytic Leukemia
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Naval G. Daver
Elite in Acute Myelomonocytic Leukemia
Dr. Naval G. Daver
Hematology Oncology | Oncology | Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Naval G. Daver
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Daver is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Hagop M. Kantarjian
Elite in Acute Myelomonocytic Leukemia
Dr. Hagop M. Kantarjian
Oncology | Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Hagop M. Kantarjian
Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist and a Hematologist in Houston, Texas. Dr. Kantarjian is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Radiation, Drug, Biological, Procedure
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell transplant in treating adult patients with cancers of blood-forming cells of the bone marrow (myeloid malignancies) that are at high risk of coming back after treatment (...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Who is this study for: Adult patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Decitabine, Filgrastim, Fludarabine, Gemtuzumab, Idarubicin
Study Phase: Phase 2

Summary: This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to st...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center